← All publications

Sub-stoichiometric Degradation is Dispensable for Potent PROTACs: A Case Study for Irreversible Covalent BTK Degraders

Cheng R, Lin H, Yu X, … Wang J · bioRxiv 2026 · bioRxiv preprint

BTK Tyrosine kinase Covalent inhibitor kinetics PhosphoSens

Read the paper

More publications on BTK

Acoustic ejection mass spectrometry: An integrated pipeline for ultra-high throughput screening, reactivity profiling, and potency analysis of covalent BTK inhibitors

Cheng R, Muneer A, Hercher M, … Nemati R · SLAS Technol 2025

Exploring 2-Sulfonylpyrimidine Warheads as Acrylamide Surrogates for Targeted Covalent Inhibition: A BTK Story

Moraru R, Valle-Argos B, Minton A, … Baud MGJ · J Med Chem 2024

Bruton's tyrosine kinase inhibition reduces disease severity in a model of secondary progressive autoimmune demyelination

Evonuk KS, Wang S, Mattie J, … Marušić S · Acta Neuropathol Commun 2023

Controlling Ibrutinib's Conformations about Its Heterobiaryl Axis to Increase BTK Selectivity

Toenjes ST, Heydari BS, Albright ST, … Gustafson JL · ACS Med Chem Lett 2023

Biochemical characterization of tirabrutinib and other irreversible inhibitors of Bruton's tyrosine kinase reveals differences in on - and off - target inhibition

Liclican A, Serafini L, Xing W, … Feng JY · Biochim Biophys Acta Gen Subj 2020

Enhancing intracellular accumulation and target engagement of PROTACs with reversible covalent chemistry

Guo WH, Qi X, Yu X, … Wang J · Nat Commun 2020

AssayQuant Technologies logo

 

 

260 Cedar Hill Street
Marlboro MA 01752

Phone: +1 (508) 804-3155

      

© 2026 AssayQuant Technologies, Inc. - All Rights Reserved - Privacy Policy - Terms & Conditions - FCOI